Coronavirus epicenter a hub for clinical trials in China

A tally of ongoing clinical trials in Wuhan, the city at the center of the coronavirus outbreak

Twenty percent of industry-sponsored clinical trials in China have a site in Wuhan, the epicenter of the 2019-nCoV coronavirus outbreak, according to lists 256 industry-funded trials that are recruiting, active but not recruiting, or enrolling by invitation in Wuhan, versus 1,300 in all of China.

The large majority of the Wuhan trials are Phase III.

The tally focuses on therapeutics and excludes trials evaluating medical devices. Companies are required to register in if the trial has at least one site in the U.S., is conducted under an FDA IND, or involves a therapeutic candidate that is manufactured in the U.S.

2019-nCoV acute respiratory disease has spread quickly in China. Wuhan is now one of 16 areas in China under quarantine, according to STCN, a financial newspaper affiliated with the state-run People’s Daily.

Further analysis of the coronavirus crisis can be found at The 2019-nCoV content is free to all who visit the site.

Figure: Wuhan’s share of China’s clinical trials

Figure: Trials in Wuhan skew to late stage

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers